News & Media
Media
FEATURED
Defence Therapeutics: Our Vaccine Treatment
FEATURED
Defence Therapeutics announces 2 clinical trials for 2023
Developing Next Generation Biopharmaceutical Innovations
Making a Global Impact
Defence Therapeutics Family Office Presentation – London UK
Defence Therapeutics spotlight on BTV
News Releases
Defence’s Broad and Versatile Accum® Technology Platform Focus on Cancer Therapeutics
Vancouver, BC, Canada, September 12th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), one of the leading Canadian biotechnology companies, is pleased to announce its continuation to bringing innovative strategies aimed at targeting various indications...
Defence’s Innovative Therapeutics are Featured on Viewpoint with Dennis Quaid
Vancouver, BC, Canada, September 5, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”) a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce that Viewpoint, the educational...
Defence Successfully Completes The First Milestone of its Collaboration Agreement with Orano
Vancouver, BC, Canada, July 18, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), is pleased to announce that it has successfully reached the first milestone established in the Collaboration Agreement with Orano Support SAS on behalf of Orano SA...
Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthrough in Biotechnology
Vancouver, BC, Canada, July 4, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”) a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint with...
Defence Patent Portfolio at the Forefront of Success
Vancouver, BC, Canada, June 28, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”) is a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies. Sitting at the core of its innovative technologies is the...
Defence Manufacturing of Accutox™ CGMP Final Drug Product Optimization for its Phase I Clinical Trial at City of Hope
Vancouver, BC, Canada, June 16th 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it reached the...
Defence Begins Testing it’s Arm Vaccine Against Pancreatic Cancer
Vancouver, BC, Canada, June 6, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it mandated...
Defence Announces Additional and Final Exercises of Warrants for Gross Proceeds of Over $2.3 Million
Vancouver, BC, Canada, May 26th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that, in addition to...
Breakthrough Results: Defences Arm Vaccine Cured 100% of Animals with Pre-established Lymphoma
Vancouver, BC, Canada, May 24th 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the successful...
Defence’s Successful Accutox™ Pre-Clinical Efficacy Study Complete Ready for Phase I and Filing
Vancouver, BC, Canada, May 2nd, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immuneoncology vaccines and drug delivery technologies is please to announce the successful completion...
USPTO Grants Trademark Registration for Defence Therapeutics®
Vancouver, BC, Canada, April 27, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that the United States Patent and...